Applications of Fmoc-(S)-3-Amino-5-Hexenoic Acid in Industrial Manufacturing

Fmoc-(S)-3-Amino-5-Hexenoic Acid serves as a specialized building block for innovative peptide and chemical synthesis in multiple advanced manufacturing areas. As an original manufacturer with direct insight from plant production and downstream technical service experience, we outline below proven industrial application domains, focusing on detailed compliance, ratios, process locations, and real end products.

1. Peptide API Synthesis for Oncology Research

Active pharmaceutical ingredient (API) producers use this compound as a non-proteinogenic amino acid insert during solid-phase peptide synthesis (SPPS) to create bioactive analogues targeting cancer therapies. It supports the fabrication of constrained peptide sequences engineered for enhanced selectivity and receptor affinity in clinical research candidates and fast-track IND submissions. The raw material integrates into resin-based automated reactors via direct coupling, ensuring side-chain integrity under standard Fmoc-removal protocols. Control over geometric structure through this intermediate allows downstream purification and scale-up for preclinical and Phase I manufacturing under tight regulatory oversight.

Industry compliance standards

• USP/NF guidelines for pharmaceutical raw materials
• ICH Q7 GMP for APIs
• EU EudraLex Volume 4 (GMP: Part II)
• FDA 21 CFR 210/211 for finished drugs

Typical usage ratio

• 0.5–2 mol% in total amino acid charge, adjusted based on peptide chain design and hydrophobicity balance
• Ratio refined through target binding affinity and process validation batches

Downstream process integration

• Charged directly into SPPS coupling cycles as a protected α-alkenyl amino acid
• Subjected to sequential deprotection, peptide elongation, and global cleavage
• Followed by high-performance liquid chromatography (HPLC) purification and lyophilization

Final product types

• Peptide-based oncology investigational drugs
• Tumor-targeting peptide conjugates
• Stabilized therapeutic peptides for pre-clinical models
• Reference standards for analytical labs

2. Stapled Peptide Therapeutics Manufacturing

Peptide engineering platform companies rely on this building block to introduce C=C bonds at strategic positions within helical peptide scaffolds to enable ring-closing metathesis “stapling.” This step occurs after the main SPPS chain assembly, improving conformational stability and cell permeability of the resulting peptides. Custom staple placements using the (S)-3-Amino-5-Hexenoic Acid unit enhance protease resistance to support GMP-scale production. QA/QC departments monitor the exact position and configuration of the introduced backbone constraint via LC-MS and NMR, fulfilling stringent batch-release documentation under clinical GMP.

Industry compliance standards

• ICH Q11: Development and Manufacture of Drug Substances
• EMA GMP Guidelines
• FDA Guidance on Peptide Drug Products

Typical usage ratio

• 1–4 residues per peptide, depending on desired helix stabilization and in vivo pharmacokinetics
• Concentration optimized through analytical screening and stability studies for each clinical candidate

Downstream process integration

• Direct insertion at designated i, i+4 or i, i+7 positions in peptide chain assembly
• Ring-closing metathesis (RCM) catalyzed by Grubbs catalyst post-SPPS
• Downstream purification by reversed-phase HPLC

Final product types

• Stapled peptide clinical trial materials
• Cell-permeable peptide therapeutics
• Constrained peptide tool compounds for drug discovery

3. Oligopeptide Specialty Chemicals for Cosmetic Peptide Additives

Cosmeceutical ingredients manufacturers use this alkenyl amino acid derivative to prepare functional oligopeptides with extended side chains, enabling improved membrane affinity and controlled hydrophobicity for skin penetration. Integration occurs during automated solid-phase or liquid-phase peptide synthesis, where precise Fmoc protection supports high purity and consistent chain assembly. Downstream blending into skin-care active formulations follows internal QC for heavy metals, residual solvents, and amino acid sequence accuracy, ensuring conformance with cosmetic ingredient safety dossiers and customs approval for global export.

Industry compliance standards

• ISO 22716 Cosmetics — Good Manufacturing Practices
• EU Cosmetic Regulation (EC) No 1223/2009
• IFRA Standards

Typical usage ratio

• Up to 5 wt% in functional peptide concentrate
• Amount based on desired cell-penetration and compatibility with formulation base; adjusted after pilot stability studies

Downstream process integration

• Charged as a protected monomer during oligopeptide condensation steps
• Subjected to sequential deprotection, cleavage and formulation blending
• Final solution or lyophilized powder subjected to microbial and heavy metals testing

Final product types

• Peptide cosmetic additives for anti-aging serums
• Biofunctional skin penetration enhancers
• Stabilized peptides for whitening or anti-wrinkle creams

4. Custom Enzyme Substrate Library Synthesis

Biotech and pharmaceutical research organizations utilize this non-canonical amino acid in the synthesis of combinatorial substrate libraries for enzyme activity screening, especially for protease and ligase specificity profiling. The alkenyl side chain expands the chemical diversity space available for substrate mapping in high-throughput assays. Fmoc-protection ensures compatibility with automated multichannel peptide synthesizers. After synthesis and deprotection, QC involves identity verification by LC-MS and quantification of purity, with batch raw data included for regulated laboratory audits.

Industry compliance standards

• ISO/IEC 17025 Accreditation (laboratory testing and calibration)
• OECD Principles of GLP
• US EPA GLP Standards for Toxicology Screening

Typical usage ratio

• 1–3 residues per synthetic peptide, depending on assay design and substrate binding requirements
• Proportion defined by library diversity requirements and enzyme selectivity studies

Downstream process integration

• Entered into automated peptide synthesis platforms for library creation
• Parallel cleavage and purification prior to enzyme assay analysis
• Library plates prepared for downstream activity screening or SAR studies

Final product types

• Research peptide substrate libraries
• Tagged peptide probes for enzyme profiling
• Biochemical screening kits for pharmaceutical R&D